0001628280-25-009091.txt : 20250228 0001628280-25-009091.hdr.sgml : 20250228 20250228163627 ACCESSION NUMBER: 0001628280-25-009091 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250227 FILED AS OF DATE: 20250228 DATE AS OF CHANGE: 20250228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sibold William John CENTRAL INDEX KEY: 0001518611 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33277 FILM NUMBER: 25691070 MAIL ADDRESS: STREET 1: C/O MADRIGAL PHARMACEUTICALS, INC., FOUR STREET 2: TOWER BRIDGE, 200 BARR HARBOR DR STE 200 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MADRIGAL PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001157601 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 BARR HARBOR DRIVE, SUITE 400 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 BUSINESS PHONE: 404-380-9263 MAIL ADDRESS: STREET 1: 200 BARR HARBOR DRIVE, SUITE 400 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 FORMER COMPANY: FORMER CONFORMED NAME: SYNTA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20010815 4 1 wk-form4_1740778579.xml FORM 4 X0508 4 2025-02-27 0 0001157601 MADRIGAL PHARMACEUTICALS, INC. MDGL 0001518611 Sibold William John C/O MADRIGAL PHARMACEUTICALS, INC. 200 BARR HARBOR DRIVE, SUITE 200 WEST CONSHOHOCKEN PA 19428 1 1 0 0 President and CEO 0 Common Stock 2025-02-27 4 M 0 50000 A 104303 D Performance Restricted Stock Units 2025-02-27 4 M 0 50000 D Common Stock 50000 0 D On February 27, 2025, the Reporting Person earned 50,000 shares of common stock following the achievement of the performance and service conditions of the Performance Restricted Stock Units described in Footnote 2. Although the Issuer is irrevocably obligated to issue these shares to the Reporting Person, these shares will settle and be delivered to the Reporting Person on September 8, 2027, the fourth anniversary of the commencement of his employment with the Issuer. On September 11, 2023, the Reporting Person was granted a one-time sign-on award of performance-based restricted stock units (PSUs) with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award and is eligible to earn up to an additional 100,000 shares upon the achievement of sustained stock price appreciation hurdles. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the PSUs. /s/ Mardi Dier, as Attorney-in-Fact 2025-02-28